| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Matsunaga-Conte Prostate Cancer Research Center, Scott Department of Urology [S. F. S., E. G., C. N., W. S., J. A., T. M. W., K. M. S.], Department of Pathology [T. M. W.], and the Department of Immunology [D. M. S.], Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, and Department of Urology [M. W. K.] and Department of Biostatistics [M. W. K.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021
The association of the results reverse transcription-PCR (RT-PCR) assays for prostate-specific antigen (PSA) with prostate cancer stage and progression remains controversial. We have previously shown that RT-PCR amplification of a native human glandular kallikrein fragment (hK2-L), but not a splice-variant hK2 transcript (hK2-U), performed preoperatively on peripheral blood before radical prostatectomy is an independent predictor of metastases to lymph nodes [K. M. Slawin, et al., Cancer Res., 60: 71427148, 2000]. We evaluated the ability of preoperative peripheral blood RT-PCR for PSA and hK2 to predict prostate cancer progression after surgery. The study group consisted of 224 consecutive patients who underwent radical prostatectomy for clinically localized disease (median follow-up: 52.9 months). Also evaluated were 14 healthy men and 8 patients with hormone-naïve, prostate cancer metastatic to bone. RT-PCR for PSA, hK2-L, and hK2-U were positive in 24, 25, and 26%, respectively, of prostatectomy patients; 88, 71, and 86%, respectively, of patients with metastases to bones; 7, 14, and 36%, respectively, of healthy men. Preoperative RT-PCR-hK2-L positivity was associated with higher final Gleason sum (P = 0.028), with an increased risk of metastases to lymph nodes (P = 0.019) and with overall and aggressive disease progression (P = 0.0231 and P = 0.028, respectively). Preoperative blood RT-PCR-PSA and RT-PCR-hK2-U were not associated with characteristics or outcomes of prostate cancer. Preoperative blood RT-PCR for PSA and hK2-U are neither therapy-guiding staging tools nor prognostic indicators in patients with clinically localized prostate cancer. In contrast, preoperative RT-PCR-hK2-L status is associated with established markers of aggressive prostate cancer.
This article has been cited by other articles:
![]() |
P. Helo, A. M. Cronin, D. C. Danila, S. Wenske, R. Gonzalez-Espinoza, A. Anand, M. Koscuiszka, R.-M. Vaananen, K. Pettersson, F. K.-H. Chun, et al. Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival Clin. Chem., April 1, 2009; 55(4): 765 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maxwell, C. R. McCudden, F. Wians, and M. S. Willis Recent Advances in the Detection of Prostate Cancer Using Epigenetic Markers in Commonly Collected Laboratory Samples Lab Med, March 1, 2009; 40(3): 171 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Sutherland, S. E. Knoblaugh, P. J. Kaplan-Lefko, F. Wang, M. Holzenberger, and N. M. Greenberg Conditional Deletion of Insulin-like Growth Factor-I Receptor in Prostate Epithelium Cancer Res., May 1, 2008; 68(9): 3495 - 3504. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liao, S. Tang, J. B. Thrasher, T. L. Griebling, and B. Li Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer Mol. Cancer Ther., April 1, 2005; 4(4): 505 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Patel, P. J. Whelan, S. Prescott, S. C. Brownhill, C. F. Johnston, P. J. Selby, and S. A. Burchill The Use of Real-Time Reverse Transcription-PCR for Prostate-Specific Antigen mRNA to Discriminate between Blood Samples from Healthy Volunteers and from Patients with Metastatic Prostate Cancer Clin. Cancer Res., November 15, 2004; 10(22): 7511 - 7519. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Shariat, M. W. Kattan, E. Traxel, B. Andrews, K. Zhu, T. M. Wheeler, and K. M. Slawin Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor {beta}1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression Clin. Cancer Res., March 15, 2004; 10(6): 1992 - 1999. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Kattan, S. F. Shariat, B. Andrews, K. Zhu, E. Canto, K. Matsumoto, M. Muramoto, P. T. Scardino, M. Ohori, T. M. Wheeler, et al. The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer J. Clin. Oncol., October 1, 2003; 21(19): 3573 - 3579. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Shariat, M. W. Kattan, W. Song, D. Bernard, E. Gottenger, T. M. Wheeler, and K. M. Slawin Early Postoperative Peripheral Blood Reverse Transcription PCR Assay for Prostate-specific Antigen Is Associated with Prostate Cancer Progression in Patients Undergoing Radical Prostatectomy Cancer Res., September 15, 2003; 63(18): 5874 - 5878. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Shariat, M. P. Roudier, G. E. Wilcox, M. W. Kattan, P. T. Scardino, R. L. Vessella, S. Erdamar, C. Nguyen, T. M. Wheeler, and K. M. Slawin Comparison of Immunohistochemistry with Reverse Transcription-PCR for the Detection of Micrometastatic Prostate Cancer in Lymph Nodes Cancer Res., August 1, 2003; 63(15): 4662 - 4670. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Shariat, M. W. Kattan, S. Erdamar, C. Nguyen, P. T. Scardino, D. M. Spencer, T. M. Wheeler, and K. M. Slawin Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein J. Clin. Oncol., April 1, 2003; 21(7): 1223 - 1231. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |